Anurag S. Rathore, PhD, wins a grant and the use of scientific instruments from Agilent to further his investigation.
Anurag S. Rathore, PhD, has become the first from India to receive the Agilent Technologies Thought Leader Award. Rathore was recognized for his contributions to biopharmaceutical research and his efforts to advance the molecular characterization of biosimilars.
The characterization of biosimilars is a process that helps determine the bioequivalence of these products to reference, or original, drugs. Characterization also establishes the nature and extent of differences between biosimilar candidates and their reference products and whether these are clinically meaningful.
As recipient of the award, Rathore receives Agilent equipment and a grant to support his research. He joins 47 others who have received the Agilent awards previously.
Agilent, a 1999 spinoff from Hewlett-Packard, is a Santa Clara, California–based analytical instrumentation developer and manufacturer.
Rathore is a professor and scientist at the Indian Institute of Technology (IIT) Delhi. He earned his PhD from Yale University and currently works in the Department of Chemical Engineering at ITT Delhi. He is a member of the Parenteral Drug Association and American Chemical Society and is the author of more than 400 publications and presentations. He is also editor-in-chief of Preparative Biochemistry and Biotechnology. Information about his publications can be accessed by clicking here.
Rathore recently spoke with The Center for Biosimilars® about a study he conducted on reasons that applications for biosimilar regulatory approval fail.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability
June 20th 2024The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.
British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years
June 18th 2024British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.